The Predictive Value Of EGFR And Survivin In Neoadjuvant Chemotherapy For Breast Cancer

Background and objectiveBreast cancer is one of the most clinically common malignant tumour in women,in the first place of female malignancy,and is still rising year by year.Newly diagnosed patients with breast cancer in women each year is a considerable proportion of malignant tumor,about 60 million people have died,Europe and North America are high incidence areas of breast cancer.In recent years,with the gradual improvement of lifestyle to high protein,high calorie,high fat lifestyle,,in China,especially in the eastern developed areas,the incidence of breast cancer is close to the world level,seriously endangering the health of the majority women.Although the high Incidence rate,the mortality rate has declined year by year,which was benefited from the continuing progress of diagnosis and treatment in breast cancer,the biggest achievement is the implementation of neoadjuvant chemotherapy.Neoadjuvantchemotherapy is a Chemotherapy method for malignant tumors without distant metastasis,before the implementation of local treatment,we give cytotoxic drugs for systemic treatment firstly.Neoadjuvant chemotherapy has multiple advantages,can reduce the size of the primary tumor,reduce the clinical stage of breast cancer patients,so that the lesion which can not be surgically removed or can not be completely removed can be cured and can verify the patient's sensitivity to chemotherapy regimens.As a result of a number of neoadjuvant chemotherapy programs,in the choice of chemotherapy programs,we need to combine the actual situation of patients to choose different targeted programs.Therefore,the predictors of neoadjuvant chemotherapy have emerged and become a hot topic in current research.EGFR is the most common human epidermal growth factor receptor,Survivin is a newly discovered inhibition of apoptosis protein family members in recent years.In this study,we collect 80 cases biopsy specimens and adjacent normal breast specimens of invasive breast cancer patients who did not receive any anti-tumor therapy,These patients all have done immunohistochemistry of EGFR and survivin,To combine evaluate the expression of EGFR and survivin and to explore the predictive value of neoadjuvant chemotherapy.MethodsWe collect 80 cases biopsy specimens and adjacent normal breast specimens of invasive breast cancer patients who did not receive any anti-tumor therapy,and they were all treated in the first Affiliated Hospital of Zhengzhou University from August 2015 to August 2016.These patients all have done immunohistochemistry of EGFR and survivin,Using the statistical statistics to explor the expression of EGFR ang survivin in the specimen.And then analyze their relationship with age,tumor size,tissue grade,clinical stage and lymph node metastasis,and explore the relationship with the prognosis of breast cancer.Results1.The positive rate of EGFR in breast cancer tissues was 68.8%(55/80),which was significantly higher than that in normal breast tissues(33.8%,27/80),the difference was statistically significant(P <0.05).The positive rate of survivin in breast cancer tissues was 72.5%(58/80),which was higher than that in adjacent tissues(27.5%,22/80),the difference was statistically significant(P <0.05).2.The expression level of EGFR in breast cancer tissues was correlated with tumor size,histological grade,clinical stage and lymph node metastasis(P <0.05),The expression of Survivin in breast cancer was correlated with lymph node metastasis(P <0.05),but not with tumor size,tissue grade,clinical stage(P>0.05),Both EGFR and survivin were not related to age(P> 0.05).3.All patients,In the low expression group of EGFR,58 patients achieved pCR,cCR and PR,9 cases of high expression group reached pCR,cCR and PR, the clinical effective rate(pCR,cCR and PR)in EGFR low expression group was significantly higher than that of EGFR high expression Group(95.08% vs 47.37% P = 0.000).49 cases of survivin low expression group reached pCR?cCR and PR,14 patients with high expression of survivin reached pCR,?cCR and PR,The total clinical effective rate(pCR,cCR and PR)of survivin low expression group was significantly higher than that of high expression group(85.96% vs 60.87% P = 0.013).Conclusions1.The expression of EGFR and survivin in breast cancer tissues was higher than that in normal breast tissues(P <0.05).2.The expression level of EGFR in breast cancer tissues was correlated with tumor size,histological grade,clinical stage and lymph node metastasis(P<0.05),The expression of Survivin in breast cancer was correlated with lymphnode metastasis(P <0.05),but not with tumor size,tissue grade,clinical stage(P> 0.05),Both EGFR and survivin were not related to age(P> 0.05).3.The expression of EGFR and survivin can be used as an effective predictor of neoadjuvant chemotherapy for breast cancer.